Meeting Coverage
This quiz explores how cholesterol levels, genetic factors, and related conditions like kidney disease influence CVD risk.
Researchers at the 2025 ASCO Annual Meeting presented several new studies on small cell lung cancer testing and treatment.
Researchers at the 2025 ASCO Annual Meeting identified barriers and solutions to biomarker testing uptake in NSCLC.
Real-world uptake of ALK biomarker testing appears to be underutilized since the FDA’s 2024 approval of adjuvant alectinib.
Findings suggest trilaciclib imparts several benefits as a supportive care therapy in extensive-stage small cell lung cancer.
An abstract from the 2025 ASCO Annual Meeting compared acalabrutinib to chemoimmunotherapy for chronic lymphocytic leukemia.
Physician's Weekly has created a slideshow highlighting some of the sessions for a quick, at-a-glance overview of the ...
At the 2025 ASCO Annual Meeting, a thoracic surgeon shared best practices for performing surgery on patients with NSCLC.
The Body Roundness Index may help identify metabolically unhealthy obesity more accurately than BMI.
An indirect comparison suggests that zanubrutinib confers a significant survival advantage in CLL compared with acalabrutinib ...
Research from the 2025 ASCO Annual Meeting showed encouraging survival outcomes with second-line lurbinectedin.
A large VA database study showed that surgery improves long-term survival over radiation in veterans with early-stage ...
Presenters at the 2025 ASCO Annual Meeting shared how clinicians can optimize surgical outcomes for frail patients with ...
In type 2 diabetes, kidney function alters how lipids affect cardiovascular risk; even low LDL or non-HDL increases CVD risk ...
A patient receiving the investigational obesity drug retatrutide presented to the emergency department.
An abstract presented at the ADA 85th Scientific Sessions showed that obesity telemedicine plus GLP-1 therapy yielded ...
A novel gene panel offered predictive value for first-line treatment of SCLC with carboplatin, etoposide, and atezolizumab.
Analyses suggest squamous and nonsquamous tumors differ in immunobiology and may respond differently to the addition of LAG-3 ...
Adam Kittai, MD, discusses his analysis presented at the 2025 ASCO Annual Meeting, which identified disparities in CLL ...
Interim results from a randomized trial suggest an assay could refine treatment decisions for patients with stage Ia–IIa ...
180 Mount Airy Road Suite 205
Basking Ridge, NJ 07920
Connect
The content of this site is intended for healthcare professionals.
© 2025 Physician’s Weekly, a Formedics PropertyAny views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Physician’s Weekly, their employees, and affiliates.